Avmapki® Fakzynja® Co-Pack - Official HCP Resource

This site is intended for US healthcare professionals.

Full Prescribing Information | Patient Site | Connect With A Rep Email Sign-Up

This site is intended for US healthcare professionals.

Full Prescribing Information Patient Site Connect With A Rep Email Sign-Up

REIMAGINE

RECURRENT LGSOC

Side profile of a woman with a collage of four seasonal landscapes behind her

REIMAGINE

RECURRENT LGSOC

The FIRST treatment specifically approved for adult patients with KRAS-mutated recurrent low-grade serous ovarian cancer (LGSOC) who have received prior systemic therapy1

Trial Results Icon

Discover the efficacy data

The RAMP 201 study evaluated efficacy endpoints for ORR and DoR.

Trial Results
Discover the efficacy data

Review safety and patient management

Information on adverse events and clinical guidance for when patients are on therapy.

Safety Data

See updated efficacy and safety data based on 1 additional year of follow-up.

The National Comprehensive Cancer Network®
(NCCN®)

Avutometinib and Defactinib
(Avmapki Fakzynja Co‑Pack) has an

NCCN Category 2A Recommendation2

Video thumbnail showing Avmapki® and Fakzynja® molecules

Hear from an expert

CLINICAL PERSPECTIVES

Dr. Robert Holloway, a gynecologic oncologist, describes his clinical experience with Avmapki Fakzynja Co-Pack.

Video thumbnail showing Avmapki® and Fakzynja® molecules

Explore the science

MECHANISM OF ACTION

Avmapki Fakzynja Co‑Pack is the first approved combination treatment that inhibits multiple targets in two different pathways involved in the growth of LGSOC.1

PATIENT PROFILES

PATIENT PROFILES

Examine two hypothetical patient journeys that involve recurrence of KRAS-mutated LGSOC.

VIEW PROFILES

Dosing information

Learn about the dosing schedule and dosing modifications for adverse events.

DOSING

DoR, duration of response; ORR, overall response rate.

References: 1. Avmapki Fakzynja Co‑Pack. Prescribing Information. Verastem, Inc. 2025. 2. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Ovarian Cancer Including Fallopian Tube Cancer and Primary Peritoneal Cancer V4.2026. © National Comprehensive Cancer Network, Inc. 2026. All rights reserved. Accessed April 16, 2026. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.

INDICATION

Avmapki Fakzynja Co‑Pack is indicated for the treatment of adult patients with KRAS-mutated recurrent low-grade serous ovarian cancer (LGSOC) who have received prior systemic therapy.

This indication is approved under accelerated approval based on tumor response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.

IMPORTANT SAFETY INFORMATION

Warnings and Precautions

  • Ocular Toxicities: Ocular toxicities, including visual impairment and vitreoretinal disorders, occurred. Perform comprehensive ophthalmic evaluation at baseline, prior to cycle 2, every three cycles thereafter, and as clinically indicated. Withhold Avmapki Fakzynja Co‑Pack for ocular toxicities until improvement at the same or reduced dose. Permanently discontinue Avmapki Fakzynja Co‑Pack for any grade 4 toxicity.
  • Serious Skin Toxicities: Skin toxicities, including photosensitivity and severe cutaneous adverse reactions (SCARs), occurred. Adhere to concomitant medications. Monitor for skin toxicities and interrupt, reduce or permanently discontinue Avmapki Fakzynja Co‑Pack based on severity, tolerability and duration.
  • Hepatotoxicity: Monitor liver function tests prior to each cycle, on day 15 of the first 4 cycles, and as clinically indicated. Withhold, reduce or discontinue Avmapki Fakzynja Co‑Pack based on severity and persistence of abnormality.
  • Rhabdomyolysis: Monitor creatine phosphokinase prior to the start of each cycle, on day 15 of the first four cycles, and as clinically indicated. If increased CPK occurs, evaluate patients for rhabdomyolysis or other causes. Withhold, reduce or permanently discontinue Avmapki Fakzynja Co‑Pack based on severity and duration of the adverse reaction.
  • Embryo-Fetal Toxicity: Avmapki Fakzynja Co‑Pack can cause fetal harm. Advise patients of the potential risk to a fetus and to use effective contraception.

Adverse Reactions

The most common (≥ 25%) adverse reactions, including laboratory abnormalities, were increased creatine phosphokinase, nausea, fatigue, increased aspartate aminotransferase, rash, diarrhea, musculoskeletal pain, edema, decreased hemoglobin, increased alanine aminotransferase, vomiting, increased blood bilirubin, increased triglycerides, decreased lymphocyte count, abdominal pain, dyspepsia, dermatitis acneiform, vitreoretinal disorders, increased alkaline phosphatase, stomatitis, pruritus, visual impairment, decreased platelet count, constipation, dry skin, dyspnea, cough, urinary tract infection, and decreased neutrophil count.

Drug Interactions

  • Strong and moderate CYP3A4 inhibitors: Avoid concomitant use with Avmapki Fakzynja Co‑Pack.
  • Strong and moderate CYP3A4 inducers: Avoid concomitant use with Avmapki Fakzynja Co‑Pack.
  • Warfarin: Avoid concomitant use of Avmapki Fakzynja Co‑Pack with warfarin and use an alternative to warfarin.
  • Gastric acid reducing agents: Avoid concomitant use of Avmapki Fakzynja Co‑Pack with proton pump inhibitors (PPIs) or H2 receptor antagonists. If use of an acid-reducing agent cannot be avoided, administer Fakzynja 2 hours before or 2 hours after the administration of a locally acting antacid.

Use in Specific Populations

  • Lactation: Advise not to breastfeed.
  • Fertility: May impair fertility in males and females.

Click here for full Prescribing Information